English

• 10 Jan, 2024
  Spago Nanomedical proceeds to the next dose level in the phase I/IIa study Tumorad-01
• 15 Dec, 2023
  Spago Nanomedical reports positive top line data from clinical phase IIa study SPAGOPIX-02 in patients with endometriosis
• 13 Dec, 2023
  Spago Nanomedical carries out a directed issue of shares to guarantors following the completed rights issue
• 12 Dec, 2023
  Rights issue in Spago Nanomedical partially registered
• 7 Dec, 2023
  First patient dosed in Spago Nanomedical’s clinical phase I/IIa study within the Tumorad® program
• 27 Nov, 2023
  Spago Nanomedical announces outcome of the rights issue
• 23 Nov, 2023
  Last day of the subscription period in Spago Nanomedical’s rights issue
• 14 Nov, 2023
  Nomination committee appointed for Spago Nanomedical’s Annual General Meeting 2024
• 9 Nov, 2023
  The subscription period in Spago Nanomedical’s rights issue begins today
• 7 Nov, 2023
  Spago Nanomedical publishes prospectus in connection with forthcoming rights issue